The $14-million colchicine study was funded by the Quebec government and several organizations. Amid the controversy, the Quebec provincial government's clinical research institute (known by its French initials as the INESSS) quickly undertook its own detailed analysis of the colchicine study. Finding inconclusive, INESSS saysThe $14-million colchicine study, funded in part by the Quebec government, was launched in March, initially with the aim of recruiting 6,000 people in six different countries. But following a close reading of those results, the advisory body determined there was insufficient evidence to draw firm conclusions about the benefits of colchicine for COVID-19 patients. In the meantime, COVID-19 patients interested in using the drug should have a discussion with their physician, said Boileau.

Source: CBC News February 05, 2021 00:45 UTC